Introduction {#sec1-1}
============

Thalassemia is an autosomal recessive disorder characterized by decreased synthesis of one or more hemoglobin polypeptide chains.\[[@ref1]\] The lack of polypeptide chain interferes with hemoglobin synthesis, erythroid precursor maturation, and function.\[[@ref1]\] β-thalassemia major patients have severe anemia due to partial or total suppression of β-globin chain synthesis.\[[@ref1]\] Regular red blood cell (RBC) transfusion support is the main treatment for these patients, which alleviates anemia by significantly suppressing the hyperactive erythropoiesis as well as inhibiting the excessive iron absorption from the gastrointestinal tract.\[[@ref2]\] One of the adverse complications of RBC transfusion is alloimmunization to erythrocyte antigens, especially in chronically transfused patients.\[[@ref3]\] Alloimmunization further complicates the transfusion therapy by inducing hemolytic transfusion reactions in some patients as well as limiting the availability of compatible blood.\[[@ref3]\]

Different rates of alloimmunization to RBC antigens have been reported in β-thalassemia major patients ranging from 2.87% to 37% in various studies.\[[@ref4][@ref5]\] Alloantibodies against Rhesus (Rh) and Kell blood group systems are the most common alloantibodies identified in a number of the studies.\[[@ref6][@ref7][@ref8]\] Transfusion of leukoreduced and extended phenotype matched RBCs has been recommended to prevent alloimmunization.\[[@ref3][@ref9]\] Moreover, RBC autoantibodies may develop in transfusion-dependent thalassemia patients.\[[@ref10]\] Although autoantibodies appear less frequently than alloantibodies, they can result in clinical hemolysis and cause difficulties in finding compatible blood for transfusion therapy.\[[@ref10]\] The aim of this study was to evaluate the frequency of alloimmunization and autoimmunization to erythrocyte antigens in β-thalassemia major patients and to identify the common alloantibodies.

Materials and Methods {#sec1-2}
=====================

Patients and blood samples {#sec2-1}
--------------------------

Our study population consisted of 49 β-thalassemia major patients (females, n = 24; males, n = 25) from the northwest of Iran. The patients were regular recipients of blood transfusion at intervals of 2-5 weeks. The mean age of the patients was 18.59 ± 8.16 years (range: 2-40 years). The clinical and transfusion records of all the patients were examined for age and sex at first transfusion, splenectomy, frequency of transfusion, exposure to leukoreduced blood, and the presence of alloimmunization or autoimmunization. After informed consent, 5 mL of blood was collected from each patient in vacutainer tubes containing ethylene diamine tetraacetic acid disodium (Na~2~ -EDTA), and the plasma was separated and stored at -20˚C until the tests were performed in batches. This study was approved by the Ethics Committee of Zanjan University of Medical Sciences, Zanjan, Zanjan Province, Iran.

Alloantibody screening and identification {#sec2-2}
-----------------------------------------

Commercially available triplet antibody screen reagent red blood cells (Alpha Laboratories-Z451, 40 Parham Dr, Eastleigh SO50 4NU, United Kingdom) were used for screening of irregular alloantibodies by the standard tube method. New antibodies to RBC antigens were detected using standard blood bank methods (saline, 37°C with albumin, and Coomb\'s phases). Antibody screen-positive samples were subjected to antibody identification procedure using a 10-cell panel of reagent red blood cells (Alpha Laboratories-Z471, 40 Parham Dr, Eastleigh SO50 4NU, United Kingdom) with known antigens.

Autoantibody detection {#sec2-3}
----------------------

A polyspecific antiglobulin reagent was used to perform direct antiglobulin test (DAT) using a 3-5% suspension of patients' RBCs and appropriate controls. In cases with positive DAT result, the test was repeated using a monospecific antiglobulin reagent. The results were read macroscopically and microscopically, and all negative results were confirmed by adding Coomb\'s control cells.

It is important to remember that a DAT test may be positive in many conditions other than the presence of autoantibody including intravenous administration of immunoglobin G (IgG), patients with neonatal hemolytic disease, bone marrow transplantation, administration of some drugs, infections, acute and chronic leukemia and is rarely positive in healthy individuals.\[[@ref11]\] We assumed the presence of autoantibody in patients with positive DAT result since the prevalence of the abovementioned conditions was quite rare in our study population. However, definitive identification of an autoantibody requires that all DAT positive samples are subjected to the elution process, and the eluted antibody is subsequently identified using a panel of reagent RBCs. The specificity of antibody should be compared with a predefined phenotype of patient red blood cells to determine if it is directed against a self-antigen (autoantibody) or a foreign antigen (alloantibody). Because of limitations in our laboratory and considering that only one of the studied patients had positive DAT, we did not perform elution and adsorption studies.

Statistical analysis {#sec2-4}
--------------------

Statistical analysis was performed using Statistical Package for the Social Sciences version 16 (SPSS Inc, Chicago, IL, USA). All data were statistically analyzed using Student\'s *t*-test and chi-square test. *P* \< 0.05 was considered statistically significant.

Results {#sec1-3}
=======

A total of 49 β-thalassemia major patients including 25 (51%) males and 24 (49%) females were enrolled in the study. The mean age of the alloimmunized and nonalloimmunized patients was 21.12 ± 6.19 years and 18.12 ± 8.46 years, respectively. The difference in mean age was not statistically significant by Student\'s *t*-test (*P* = 0.85). Additionally, the correlation between the age at the start of transfusion and alloimmunization status was not statistically significant (*P* = 0.78). The age distribution of β-thalassemia major patients is represented in [Table 1](#T1){ref-type="table"}.

###### 

Age distribution of thalassemia patients
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In the current study, eight subjects were found to be positive for RBC alloantibodies. Thus, the prevalence of alloimmunization in our study population was 16.32% with 95% confidence interval (CI) of 8.5-29.0%. Collectively, 10 alloantibodies were detected in eight alloimmunized patients, and the most commonly identified alloantibody was anti-K (Kell) followed by anti-Rh (E, c antigens) \[[Table 2](#T2){ref-type="table"}\]. The profiles of alloimmunized thalassemia patients are given in [Table 3](#T3){ref-type="table"}. As shown in the Table, six alloimmunized patients (75%) developed single alloantibody while two alloimmunized patients (25%) developed dual alloantibody. Moreover, only one (2.04 %) β-thalassemia major patient developed autoantibody as well as alloantibody. [Table 4](#T4){ref-type="table"} represents the incidence of ABO blood groups among alloimmunized and nonalloimmunized patients. As shown in this table, the prevalence of antibody was higher in patients with blood group A (62.5%). Chi-square test showed significant differences in the distribution of blood group A between the alloimmunized and nonalloimmunized patients (*P* = 0.01).

###### 

Frequency of various anti-red blood cell alloantibodies in alloimmunized β-thalassemia major patients
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###### 

Profile of alloimmunized β-thalassemia major patients
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###### 

Alloimmunization incidence by blood groups
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Moreover, our results revealed that 5 out of 25 males (20%) and 3 out of 24 females (12.5%) showed evidence of alloimmunization. Chi-square test showed no significant correlation between gender and alloimmunization status (*P* = 0.47).

The majority of patients (85.71%) received ABO and Rh (D) matched, homologous leukoreduced packed RBC while a minority of them (14.29%) received ABO and Rh (D) matched, homologous nonleukoreduced packed RBC. As shown in [Table 5](#T5){ref-type="table"}, the rate of alloimmunization was significantly higher in patients receiving nonleukoreduced packed RBC compared with those receiving leukoreduced packed RBC (57.14% vs 9.53%) (*P* = 0.001).

###### 

Alloimmunization incidence in patients receiving leukoreduced and nonleukoreduced packed red blood cell

![](AJTS-10-88-g005)

Moreover, 17 out of 49 patients (34.7%) underwent splenectomy, out of which only 3 patients were alloimmunized and the remaining 14 patients were not alloimmunized. The comparison of splenectomy as a risk factor between patients with and without alloimmunization (37.5% vs 34.1%) was not statistically significant (*P* = 0.85). Finally, the correlation between hemoglobin levels (*P* = 0.93), number of transfused units (*P* = 0.7), and age at the start of transfusion (*P* = 0.45) and alloimmunization was not significant. [Table 6](#T6){ref-type="table"} represents the antigen matching stringency levels based on different antigen sets.

###### 

Antigen matching stringency levels\[[@ref9]\]
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Discussion {#sec1-4}
==========

In the present study, we examined the prevalence of common alloantibodies in multitransfused β-thalassemia major patients from the northwest of Iran. We reported an alloimmunization rate of 16.32%, with 95% CI of 8.5-29.0%. The rates of alloimmunization in other parts of Iran have been reported as follows: 7.4% (Tehran), 5.34% (Fars Province), 18.7% (Southwest of Iran), 2.87% (northeast of Iran), and 17.9% (southeast of Iran).\[[@ref5][@ref12][@ref13][@ref14][@ref15]\]

The most common clinically significant alloantibodies detected in our study were directed against K antigen in the Kell system and E, c antigens in the Rh system. Similarly, Ameen *et al*. reported anti-Kell and anti-Rh as the most commonly identified alloantibodies in their study.\[[@ref16]\] In a recent multicenter study from Iran, Azarkeivan *et al*. screened 835 thalassemia patients for unexpected RBC alloantibody and reported an alloimmunization rate of 12.1% with anti-K as the most commonly identified alloantibody.\[[@ref17]\] Furthermore, Saied *et al*. investigated 95 Egyptian β-thalassemic patients and reported anti-Kell and anti-E as the most commonly identified alloantibodies.\[[@ref7]\]

The frequency of alloimmunization in our thalassemia patients (16.32%) was lower than that reported in thalassemia patients from Taiwan (37%), Egypt (28.4%), and Kuwait (30%)\[[@ref4][@ref7][@ref8]\] but was higher than the frequency reported in patients from Pakistan (3.75%), Italy (5.2%), Greece (3.7%), India (5.64%), and Malaysia (8.6%).\[[@ref18][@ref19][@ref20][@ref21][@ref22]\] One of the most important reasons for the relatively high alloimmunization rate in our thalassemia patients may be transfusion of nonleukoreduced RBC units in a number of patients. As indicated in [Table 5](#T5){ref-type="table"}, over 50% of our alloimmunized thalassemia patients received nonleukoreduced RBC units.

Factors affecting alloimmunization are complex, and at least three contributing factors may explain the differences in alloimmunization rate: RBC antigenic difference between the donor and recipient, the recipient\'s immune status, and the immunomodulatory effect of the allogenic blood transfusion on recipient\'s immune system.\[[@ref10]\] In addition, differences in immunogenicity of various RBC antigens may affect the rate of alloimmunization. The Kell and Rh blood group system antigens are strong immunogens; therefore, the majority of studies including ours have reported alloantibody specificity to Kell and Rh blood group systems.\[[@ref14][@ref15][@ref17][@ref18]\]

Moreover, the sensitivity of the laboratory method used for antibody screening and identification (gel centrifugation techniques vs classical tube techniques) significantly affects the efficiency of antibody identification procedures and alloimmunization incidence. A study by Delaflor-Weiss *et al*. demonstrated increased overall incidence of clinically significant antibodies identified by the gel method as compared to the tube method without significant differences in the nonspecific reactions.\[[@ref23]\]

In our study, patients transfused with nonleukoreduced RBCs had a higher rate of alloimmunization compared with patients transfused with leukoreduced RBCs. The immunomodulatory role of white blood cells in transfused blood may explain this observation. Leukocytes in blood components may downregulate T-helper cell type 1 (Th1) immune response and direct the recipient toward T-helper cell type 2 (Th2) responses. Such skewing toward type 2 immunity may enhance alloantibody formation.\[[@ref24]\] Our results were consistent with the results of Singer *et al*. and Hussein *et al*. who showed a lower rate of alloimmunization in patients transfused with leukoreduced RBCs.\[[@ref3][@ref10]\] The standard of leukoreduction in Iran is fewer than 5 × 10^6^ donor white blood cells per component.

Unlike alloimmunization, the rate of autoimmunization was very low (2.14%) in our study. A low rate of autoimmunization, together with a high rate of alloimmunization, has been reported in other studies.\[[@ref3][@ref22]\]

Currently, providing compatible blood for alloimmunized thalassemia patients presents a major challenge. Transfusion of extended phenotype matched blood can be useful in the prevention of alloimmunization.\[[@ref9][@ref24]\] Klapper *et al*.\[[@ref9]\] used an extended phenotype matched blood transfusion based on the levels of antigen matching stringency \[[Table 6](#T6){ref-type="table"}\]. Retrospectively, if our thalassemia patients had been transfused with extended phenotype matched blood for Kell- K, Rh-E, and Rh-c antigens or level 2 antigen matching stringency \[[Table 6](#T6){ref-type="table"}\], the alloimmunization rate would have been reduced by 75% (in six out of eight alloimmunized patients).

It has been reported that an early age at the start of transfusion therapy may offer some level of immune tolerance and protect against alloimmunization.\[[@ref10][@ref20][@ref25]\] However, in our study, the incidence of alloimmunization was not influenced by the age at which transfusion was started. One possible explanation for this finding may be the small sample size of alloimmunized patients in our study. Moreover, the number of transfused blood units, genetic and ethnic background of the patients and blood donors, and the immune status of the patients may affect the alloimmunization rate. Our result was consistent with other studies reporting no association between the age at the start of transfusion therapy and alloimmunization rate.\[[@ref3][@ref12][@ref14][@ref22]\]

Regarding the frequency of blood transfusion in patients, the average number of transfused units per year was 18.25 U/year in alloimmunized patients compared with 17.50 U/year in nonalloimmunized patients. The correlation between alloimmunization and the frequency of blood transfusion was not significant in our study, which was inconsistent with the results of other studies.\[[@ref25]\] The possible reasons for these controversial results may be explained by the fact that in addition to the number of transfused units, many concomitant factors such as ethnic similarity between patients and blood donors, the time interval between blood transfusions, and type of transfused blood (leukoreduced vs nonleukoreduced) may affect the alloimmunization incidence in different studies.\[[@ref3][@ref7][@ref10][@ref26]\]

Splenectomy is also considered as a risk factor for alloimmunization.\[[@ref10]\] However, in the current study, there was no statistically significant difference between splenectomized and nonsplenectomized patients regarding the alloimmunization rate (37.5% vs 34.1%; *P* = 0.85). This is a contrast to the study of Hussein *et al*. (2014) who observed a higher rate of alloimmunization in splenectomized patients.\[[@ref3]\] However, our results were in accordance with other studies that reported an insignificant association between splenectomy and alloimmunization rate in thalassemia patients.\[[@ref25][@ref27]\] These conflicting results may be related to various factors including RBC transfusion burden, timing of initial RBC antigen exposure (presplenectomy vs postsplenectomy), and the life span of transfused RBC.\[[@ref28]\]

Conclusion {#sec1-5}
==========

The rate of RBC alloimmunization is relatively high in our patients. Determination of RBCs phenotype before beginning chronic blood transfusion as well as selective transfusion of leukoreduced and phenotypically matched RBC units for Kell (K) and Rh (E, c) antigens may help reduce the alloimmunization rate in chronic transfusion patients.
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